The Drugs Controller General of India (DCGI) has given permission for the Phase III trial of Russia’s Sputnik Light Vaccine in the country. Sputnik Light is a single dose vaccine used against COVID-19. This approval has been given after a recent study published in the medical journal ‘The Lancet’. It has been found in this study that Sputnik Light has shown an efficacy of 78.6% to 83.7% against COVID-19, which is much higher than most two-dose vaccines. In July, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) had refused to approve the emergency use of Sputnik Light.